Abstract:Objectives To investigate the design, conduct, and analysis of adaptive trials through a systematic survey and provide recommendations for future adaptive trials. Study Design and Setting We systematically searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases up to January 2020. We included trials that were self-described as adaptive trials or applied adaptive designs. We identified three frequently used adaptive designs and summarized their methodological details in terms of design, conduct, and analysis. Lastly, we provided recommendations for future adaptive trials. Results We included a total of 128 trials in this study. The primary motivations for using adaptive design were to speed up the trials and facilitate decision-making (n=29, 31.5%). The three most frequently used methods were group sequential design (GSD) (n=71, 55.5%), adaptive dose-finding design (ADFD) (n=35, 27.3%), and adaptive randomization design (ARD) (n=26, 20.3%). The timing and frequency of interim analysis were detailed in three-fourths of the GSD trials (n=55, 77.5%) and in half of the ADFD trials (n=19, 54.3%); however, more than half of the ARD trials (n=15, 57.7%) did not provide this information. Some trials selected a different outcome than the primary outcome for interim analysis (GSD: n=7, 12.7%; ADFD: n=8, 27.6%; ARD: n=7, 50.0%), but the majority of these trials did not provide explicit reasons for this choice (GSD: n=7, 100.0%; ADFD: n=7, 87.5%; ARD: n=5, 71.4%). More than half (n=76, 59.4%) of trials did not mention the accessibility of supporting documents, and two-thirds (n=86, 67.2%) did not state the establishment of independent data monitoring committees (IDMCs). Moreover, unplanned adjustments were observed during the conduct of one-sixth adaptive trials (n=22, 17.2%). Based on our findings, we provide 14 recommendations for improving adaptive trials in the future. Conclusions Substantial improvements were needed in methods of adaptive trials, particularly in the areas of interim analysis, the establishment of IDMCs, and unplanned adjustments. In this study, we offer recommendations fr0m both general and specific aspects for researchers to carefully design, conduct, and analyze adaptive trials.

[How to Report Adaptive Design Randomized Trials-a Interpretation of International Reporting Guideline ACE].

The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration

Adaptive designs were primarily used but inadequately reported in early phase drug trials

The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials

Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension

A New Family of Covariate-Adjusted Response Adaptive Designs and Their Properties

Adaptive Designs for Sequential Experiments

Reporting and communication of sample size calculations in adaptive clinical trials: a review of trial protocols and grant applications

CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration

Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration

A Cross-sectional literature survey showed the reporting quality of multicenter randomized controlled trials should be improved

Protocol of the CONSORT and SPIRIT Extension for multicenter clinical trials

Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration

The CONSORT Statement: Uniform Requirements for Reporting Randomized Controlled Trials

A systematic survey of adaptive trials shows substantial improvement in methods is needed

CONSORT 2010 statement: extension to randomised crossover trials

Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration

[Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extensionDiretrizes para relatórios de ensaios clínicos com intervenções que utilizam inteligência artificial: a extensão CONSORT-AI]

The Consolidated Standards of Reporting Trials (CONSORT): Guidelines for Reporting Randomized Trials

Does the CONSORT checklist for abstracts improve the quality of reports of randomized controlled trials on clinical pathways?

Reporting Quality of Social and Psychological Intervention Trials: A Systematic Review of Reporting Guidelines and Trial Publications